OBJECTIVE
To analyze the pharmaceutical market in segment of medicines for pediatrics.
MATERIAL AND METHODS
We analyzed the State Register of Medicines data as of 01.01.2023 and instructions for medicines introduced into civil circulation in the Russian Federation. Processing of information and results was performed using MS Excel 2021 software. We assessed the assortment matrix taking into account coefficients of breadth, completeness and depth.
RESULTS
There are 9871 positions in national market in segment of drugs approved for patients younger 18 years old. According to registration certificate owner data, the share of Russian-made drugs is 72.09%. Antimicrobial drugs for systemic therapy are the most common cluster (17.42%). Structuring by dosage forms demonstrates predominance of oral drugs (39.88%). Price segmentation of vital and essential drugs, determined by marginal selling prices of manufacturers, indicates uniform distribution of drugs in three price categories. Assortment analysis demonstrate all groups of medicines with potential variability of commodity units within the analyzed segment. Maximum completeness and depth coefficients were observed in the groups of drugs for the treatment of respiratory diseases (0.80 and 0.94, respectively), skin lesions (0.77 and 0.70), digestive system and metabolism (0.63 and 0.82), as well as antimicrobials for systemic therapy (0.77 and 0.88). The largest update indices were recorded in categories of medicines for the treatment of diseases of musculoskeletal system (0.42), antimicrobials (0.34), drugs for the treatment of sensory organs (0.34) and respiratory system (0.34). Macro-contour indicators demonstrate the need to shift traditional developments towards innovative drugs based on the concept of modern pediatric science.
CONCLUSION
Available range of medicines demonstrates insufficient filling with drugs in special pediatric dosage forms ensuring compliance with modern concepts of pediatrics and precise dosing of active substances depending on age. Medical, organizational, pharmaceutical and legal aspects are essential for development, production and use of medicinal products in children.
